Metis Global Partners LLC Trims Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Metis Global Partners LLC lessened its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 12.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,356 shares of the company’s stock after selling 2,111 shares during the period. Metis Global Partners LLC’s holdings in GE HealthCare Technologies were worth $1,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. LGT Financial Advisors LLC raised its holdings in shares of GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of GE HealthCare Technologies during the third quarter worth $26,000. Ashton Thomas Securities LLC purchased a new position in shares of GE HealthCare Technologies during the third quarter worth $26,000. Darwin Wealth Management LLC purchased a new position in shares of GE HealthCare Technologies during the third quarter worth $31,000. Finally, Continuum Advisory LLC raised its holdings in shares of GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GEHC shares. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Citigroup lifted their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $97.67.

GE HealthCare Technologies Stock Down 1.0 %

Shares of NASDAQ GEHC opened at $86.45 on Tuesday. The company’s 50-day simple moving average is $86.31 and its 200-day simple moving average is $86.14. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80. The firm has a market cap of $39.53 billion, a price-to-earnings ratio of 19.97, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. Equities analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.